论文部分内容阅读
目的:探讨冷沉淀凝血因子在肝硬化患者中的作用。方法:选择110例肝硬化患者,按照是否输入冷沉淀分为2组,观察组64例在常规治疗的基础上输注冷沉淀凝血因子,对照组46例常规治疗,所有患者输注前、输注后24h内进行凝血4项检测,血常规,D-二聚体测定。同时观察2组患者的输注病毒灭活冰冻血浆,去白悬浮红细胞,冷沉淀等成分血的情况以及患者的康复情况。结果:观察组的患者输注冷沉淀后的凝血酶原时间(PT),凝血酶时间(TT),部分凝血活酶时间(APTT)均明显缩短,纤维蛋白原(Fbg)含量增加,D-二聚体转为阴性。观察组输注病毒灭活冰冻血浆,去白悬浮红细胞等成分血比对照组少,2组比较差异有统计学意义(P<0.01)。结论:在肝硬化患者中输入冷沉淀凝血因子可提高血循环中凝血因子及纤维蛋白原等凝血物质的含量,缩短凝血时间,纠正凝血异常,值得临床推广。
Objective: To investigate the role of cryoprecipitate in cirrhotic patients. Methods: One hundred and ten patients with cirrhosis were divided into two groups according to whether they were cryoprecipitated or not. Sixty-four patients in the observation group were given cold coagulation factor on the basis of routine treatment, and 46 patients in the control group were treated routinely. All patients before and after infusion Note 24h after coagulation within 4 tests, blood, D-dimer determination. At the same time, two groups of patients were observed inactivation of frozen plasma infusion of virus, to white suspension of red blood cells, cold sedimentation and other components of the blood situation and the patient’s recovery. Results: The prothrombin time (PT), thrombin time (TT) and partial thromboplastin time (APTT) of the patients in observation group were significantly shortened, Fbg content increased, D- Dimer turned negative. In the observation group, virus inactivation of frozen plasma was less than that in the control group, and there were significant differences between the two groups (P <0.01). Conclusion: In the patients with cirrhosis, cryoprecipitated coagulation factor can increase the blood coagulation factors and fibrinogen and other coagulation substances, shorten the clotting time and correct coagulation abnormalities, which is worthy of clinical promotion.